title: Effects of adenosine triphosphate dependent potassium channel opener on bladder overactivity in rats with cerebral infarction.
abstract: OBJECTIVE
  We evaluated the effect of the adenosine triphosphate dependent K channel opener KRN2391 (N-cyano-N' -(2-nitroxyethyl)-3-pyridinecarboximidamide methanesulfonate) (Kirin Brewery Co., Gunma, Japan) on bladder overactivity induced by middle cerebral artery occlusion.
  
  
  METHODS
  At 7 days after implantation of a bladder catheter in male Sprague-Dawley rats a cannula for intracerebroventricular administration was implanted and the left middle cerebral artery was occluded with 4-zero monofilament nylon thread. At 22 hours after the induction of cerebral ischemia saline was infused into the bladder at a constant rate (200 microl. per minute) and a cystometrogram was obtained with the rat in the conscious state. KRN2391 (5 microl.) was administered in intracerebroventricular fashion at graded doses (0.15 to 15 microg.).
  
  
  RESULTS
  Bladder capacity in conscious rats was significantly reduced after left middle cerebral artery occlusion. Intracerebroventricular administration of KRN2391 significantly increased bladder capacity in cerebral infarcted but not in sham operated rats.
  
  
  CONCLUSIONS
  These results show that a adenosine triphosphate dependent K channel opener may be useful for neurogenic bladder overactivity after cerebral infarction via action on the central nervous system.
authors.affiliation: Department of Urology, Kanazawa University School of Medicine, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kontani
authors.forename: Tomoko
authors.initials: T
authors.lastname: Tanaka
authors.forename: Kazuto
authors.initials: K
authors.lastname: Komatsu
authors.forename: Mikio
authors.initials: M
authors.lastname: Namiki
authors.forename: Osamu
authors.initials: O
authors.lastname: Yokoyama
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D020244:Infarction, Middle Cerebral Artery / Q000503:physiopathology*; D007276:Injections, Intraventricular; D008297:Male; D011149:Pons / Q000187:drug effects / Q000503:physiopathology; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D001750:Urinary Bladder, Neurogenic / Q000503:physiopathology*; D014563:Urodynamics / Q000187:drug effects* / Q000502:physiology
chemical_list: D015221:Potassium Channels; D011725:Pyridines; C070492:N-cyano-N'-(2-nitroxyethyl)-3-pyridinecarboximidamide methanesulfonate